Table 2. MSKCC cohort: comparison of metabolic pathway scores between hormone-naïve prostate cancer and benign tissue.
| Metabolic Pathway | t-test |
|---|---|
| Choline_PhosphoCholine | 0.0002 (upregulated) |
| Proline Synthesis | 0.0029 (upregulated) |
| Pyruvate to Acetyl CoA | 0.0092 (downregulated) |
| Lipogenesis | 0.0580 (downregulated) |
| Proline Degradation | 0.0708 (downreguated) |
| Cholesterogenesis | 0.0983 |
| Fatty Acid B-oxidation | 0.1059 |
| TCA Cycle | 0.1086 |
| Oxpho II Complex | 0.1096 |
| CDP-Choline | 0.1365 |
| Oxpho IV Complex | 0.1618 |
| Fatty Acid Activation | 0.2099 |
| Glycolysis | 0.2573 |
| One-carbon metabolism | 0.3883 |
| Oxpho I Complex | 0.4015 |
| Lactate generation | 0.4800 |
| Gluconeogenesis | 0.5183 |
| Glutaminolysis | 0.5615 |
| Ketolysis | 0.5985 |
| Ketogenesis | 0.6802 |
| Oxpho III Complex | 0.7039 |
| Oxpho V Complex | 0.7095 |
| Pentose Phosphate Pathway | 0.7922 |
Using the Students t-test (p<0.05) prostate cancer (n=112) log2 gene expression for each pathway was compared to benign tissue (n=28) log2 gene expression for each pathway.